For patients trying to avoid weight gain, diabetes risk, and the metabolic complications that haunt much of the antipsychotic class, two drugs come up most often in clinic conversations: lurasidone (Latuda) and ziprasidone (Geodon). Both are sometimes called "metabolically friendly" — and the label is mostly earned. They are not interchangeable, though, and each has practical issues that often determine the choice.
Lurasidone and ziprasidone are the two atypical antipsychotics with the lightest weight and metabolic profiles, but lurasidone has stronger bipolar-depression evidence and once-daily dosing, while ziprasidone has the practical disadvantage of strict food and dosing rules.
Receptor pharmacology
Both bind D2 and 5-HT2A receptors with high affinity. Lurasidone has additional strong affinity at 5-HT7 (potentially relevant to its mood-elevating effects) and 5-HT1A partial agonism. Ziprasidone has notable serotonin and norepinephrine reuptake inhibition, which gave it some early enthusiasm as a mood-improving antipsychotic — though the clinical importance of this is modest.
Critically, neither drug has strong H1 (histamine) or M1 (muscarinic) binding — the receptors most associated with sedation, weight gain, and metabolic effects in the rest of the class.
Efficacy
For schizophrenia, both drugs sit in the middle tier of atypical efficacy in network meta-analyses (Leucht et al., Lancet 2013; PubMed) — comparable to risperidone, somewhat behind olanzapine and clozapine. The CATIE trial showed ziprasidone with the shortest time-to-discontinuation among second-generation atypicals, partly attributed to dosing complications and modest efficacy.
For bipolar depression, lurasidone has stronger evidence and FDA approval as monotherapy. Ziprasidone does not have a bipolar-depression indication.
The food rules — a real-world deal-breaker
This is often the deciding practical issue.
- Lurasidone must be taken with at least 350 calories of food. Without food, absorption drops by roughly half, and blood levels become too low to reliably treat psychosis. This requirement is straightforward but real — patients who skip dinner or eat erratically can have unpredictable response.
- Ziprasidone must be taken with at least 500 calories of food, and is most commonly dosed twice daily. Without food, absorption can drop by more than half. The food rule is the most restrictive of any commonly used antipsychotic.
For patients with disordered eating, food insecurity, or chaotic schedules, both can be hard. Lurasidone is generally more forgiving than ziprasidone on this score because of its once-daily dosing and slightly lower calorie threshold.
Side effects compared
Weight and metabolic
Both are among the lightest atypicals on weight gain. Average year-one gain is typically 1–3 kg or less for both, with many patients gaining nothing. Both have minimal effects on lipids and glucose. This is the main reason they are chosen.
Akathisia and EPS
Both can cause akathisia — lurasidone notably so, particularly at higher doses (above 80 mg/day). Ziprasidone also can. Patients with prior akathisia on aripiprazole are at higher risk on either of these drugs.
Sedation
Lurasidone is mildly sedating; ziprasidone less so. Both are far less sedating than quetiapine or olanzapine.
QT prolongation
This is ziprasidone's most distinctive cardiovascular concern. It can prolong the QT interval more than other atypicals. Most clinicians order an ECG before starting if there are cardiac risk factors. Lurasidone has minimal QT effect. See our QT prolongation explainer.
Prolactin
Both have modest prolactin effects — less than risperidone or paliperidone, more than aripiprazole.
Dosing
- Lurasidone: 40–160 mg once daily with food (schizophrenia); 20–120 mg for bipolar depression
- Ziprasidone: 40–80 mg twice daily with food (schizophrenia); intramuscular form available for acute agitation
When lurasidone is the better choice
- Bipolar depression (specific approval and stronger evidence)
- Once-daily dosing is preferred
- Cardiac risk factors that make QT-prolonging drugs less attractive
- Patient with stable evening meal habits
When ziprasidone is the better choice
- Acute agitation in inpatient settings (intramuscular form available)
- Patient is highly motivated and able to take with substantial meals twice daily
- Generic cost is a factor (ziprasidone is generic; lurasidone is brand-only in many markets)
Both drugs absorb poorly without enough food. If eating patterns are chaotic, an antipsychotic without food restrictions — or a long-acting injectable — may be a more reliable choice.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.